ABSTRACT
Radium-223 dichloride is an alpha radionuclide therapy and approved for the treatment of castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastatic disease. In the phase 3 ALSYMPCA trial, patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastases were randomly assigned to receive Radium-223 or placebo. Radium-223 Dichloride significantly improved overall survival compared with placebo (median overall survival 14.9 vs. 11.3 months). Radium-223 significantly prolonged the time to the first SRE compared with placebo (median 15.6 vs. 9.8 months). This review aims to evaluate the position of Radium-223 treatment in current guidelines, to discuss the results of key studies and review ongoing studies.
References
1
Chiang AC, Massague J. Molecular basis of metastasis. N Engl J Med 2008;359:2814-2823.
2
Waning DL, Guise TA. Molecular mechanisms of bone metastasis and associated muscle weakness. Clin Cancer Res 2014;20:3071-3077.
3
Guise TA, Mohammad KS, Clines G, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006;12:6213-6216.
4
Proescher F. The intravenous injection of soluble radium salts in man. Radium 1913;1:9-10.
5
Ahmadzadehfar H, Essler M, Rahbar K, Afshar-Oromieh A. Radionuclide Therapy for Bone Metastases: Utility of Scintigraphy and PET Imaging for Treatment Planning. PET Clin 2018;13:491-503.
6
Yeong CH, Cheng MH, Ng KH. Therapeutic radionuclides in nuclear medicine: current and future prospects. J Zhejiang Univ Sci B 2014;15:845-863.
7
Poeppel TD, Handkiewicz-Junak D, Andreeff M, et al. EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 2018;45:824-845.
8
Morris MJ, Corey E, Guise TA, et al. Radium-223 mechanism of action: implications for use in treatment combinations. Nat Rev Urol 2019;16:745-756.
9
Den RB, George D, Pieczonka C, McNamara M. Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer: Practical Management Issues for Patient Selection. Am J Clin Oncol 2019;42:399-406.
10
Suominen MI, Fagerlund KM, Rissanen JP, et al. Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models. Clin Cancer Res 2017;23:4335-4346.
11
Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol 2017;71:630-642.
12
Elboğa U, Selçuk NA. Radionuclide Treatment in Pain Palliation. Nucl Med Semin 2020;6:423-435.
13
Oyen WJG, Sundram F, Haug AR, et al. Radium-223 Dichloride (Ra-223) for the Treatment of Metastatic Castration-resistant Prostate Cancer: Optimizing Clinical Practice in Nuclear Medicine Centers. Journal of OncoPathology 2015.
14
Schaeffer E, Srinivas S, An Y. Prostate Cancer, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network https://www nccn org/professionals/physician_gls/pdf/prostate pdf Accessed 2022.
15
Prostate cancer guidelines. European Association of Urology.
16
Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213-223.
17
Nilsson S, Cislo P, Sartor O, et al. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Ann Oncol 2016;27:868-874.
18
Sartor O, Hoskin P, Coleman RE, et al. Chemotherapy following radium-223 dichloride treatment in ALSYMPCA. Prostate 2016;76:905-916.
19
de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
20
Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371:424-433.
21
Ryan CJ, Smith MR, De Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138-148.
22
Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-1197.
23
Smith M, Parker C, Saad F, et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019;20:408-419.
24
EMA restricts use of prostate cancer medicine Xofigo. Accessed date: 2023 18.07.2023. Available from: https://www.ema.europa.eu/en/medicines/human/referrals/xofigo.
25
Shore ND, Schellhammer PF, Tutrone RF, Mariados NF, Harrelson SS. Open Label Phase II Study of Enzalutamide With Concurrent Administration of Radium 223 Dichloride in Patients With Castration-Resistant Prostate Cancer. Clin Genitourin Cancer 2020;18:416-422.
26
Maughan BL, Kessel A, McFarland TR, et al. Radium-223 plus enzalutamide versus enzalutamide in metastatic castration-refractory prostate cancer: final safety and efficacy results. Oncologist 2021;26:1006-2129.
27
Gillessen S, Choudhury A, Rodriguez-Vida A, et al. Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated safety analysis. J Clin Oncol 2021;39:5002-5002.
28
Saad F, Carles J, Gillessen S, et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol 2016;17:1306-1316.
29
Fizazi K, Beuzeboc P, Lumbroso J, et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 2009;27:2429-2435.
30
Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001;357:336-341.
31
Morris MJ, Pandit-Taskar N, Carrasquillo J, et al. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol 2009;27:2436-2442.
32
Morris MJ, Loriot Y, Sweeney CJ, et al. Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. Eur J Cancer 2019;114:107-116.
33
Accessed date. Available from: https://clinicaltrials.gov/ct2/show/NCT03574571.
34
Marshall CH, Fu W, Wang H, et al. Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer. Clin Cancer Res 2021;27:1623-1630.
35
Fong L, Morris MJ, Sartor O, et al. A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res 2021;27:4746-4756.
36
Pan E, Xie W, Ajmera A, et al. A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE). Mol Cancer Ther 2023;22:511-518.
37
Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med 2021;385:1091-1103.
38
Sartor O, Fougere C, Essler M, et al. 177Lu-Prostate-Specific Membrane Antigen Ligand After 223Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical Experience. J Nucl Med 2022;63:410-414.
39
Rahbar K, Essler M, Pabst KM, et al. Safety and Survival Outcomes of (177)Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior (223)Ra treatment: The RALU Study. J Nucl Med 2023;64:574-578.
40
Kostos L, Buteau JP, Yeung T, et al. AlphaBet: Combination of Radium-223 and [(17) (7)Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol). Front Med (Lausanne) 2022;9:1059122.
41
Dandapani SV, Wong J, Twardowski P. Review of Radium-223 and Metastatic Castration-Sensitive Prostate Cancer. Cancer Biother Radiopharm 2020;35:490-496.